| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/01/2009 | EP2042162A1 Process for producing spherical elementary granule containing readily water-soluble drug |
| 04/01/2009 | EP2042161A1 Propellant-free spray composition comprising anti-emetic agent |
| 04/01/2009 | EP2042157A1 Hair growth composition |
| 04/01/2009 | EP2042041A2 Use of benzoic acid and thymol, eugenol and piperine in animal feeding |
| 04/01/2009 | EP2041158A2 Peptide epoxyketones for proteasome inhibition |
| 04/01/2009 | EP2041153A1 New 5-thioxylopyranose derivatives |
| 04/01/2009 | EP2041152A1 D-glucopyranose 1-[3,5-bis(1,1-dimethylethyl)-4-hydroxybenzoate] compound and its derivatives, preparation thereof and uses thereof |
| 04/01/2009 | EP2041151A1 A method of preparing a glycoside of a mono- or diacylglycerol product from a plant material |
| 04/01/2009 | EP2041145A1 Azatricyclic compounds and their use |
| 04/01/2009 | EP2041144A1 Substituted benzoxepino-isoxazoles and use thereof |
| 04/01/2009 | EP2041143A1 Quinazoline derivatives, their preparation, their use as tyrosine kinase inhibitors and medicaments comprising them |
| 04/01/2009 | EP2041142A1 Spirocyclic azaindole derivatives |
| 04/01/2009 | EP2041141A2 Benzopyranopyrazoles |
| 04/01/2009 | EP2041140A2 Aziridinyl-epothilone compounds |
| 04/01/2009 | EP2041138A2 Pyrrolotriazine kinase inhibitors |
| 04/01/2009 | EP2041137A2 Pyrrolopyrimidines for pharmaceutical compositions |
| 04/01/2009 | EP2041136A2 Selective antagonists of a2a adenosine receptors |
| 04/01/2009 | EP2041135A1 8-oxoadenine derivatives acting as modulators of tlr7 |
| 04/01/2009 | EP2041134A1 Novel 1,4-diaza-bicycloý3.2.2¨nonyl pyrimidinyl derivatives and their medical use |
| 04/01/2009 | EP2041133A1 Derivatives of imidazo [1,2-a]pyridine-2-carboxamides, preparation method thereof and use of same in therapeutics |
| 04/01/2009 | EP2041131A1 Azaindole derivatives with a combination of partial nicotinic acetylcholine receptor agonism and dopamine reuptake inhibition |
| 04/01/2009 | EP2041130A1 Novel hydrate form of moxifloxacin monohydrochloride |
| 04/01/2009 | EP2041129A2 Human protein tyrosine phosphatase inhibitors and methods of use |
| 04/01/2009 | EP2041128A2 Substituted gamma lactams as therapeutic agents |
| 04/01/2009 | EP2041127A2 Indole compounds |
| 04/01/2009 | EP2041126A1 Indole compounds having affinity to the ep1 receptor |
| 04/01/2009 | EP2041124A1 Pyrazolealkanamide substituted thiophenes as ampa potentiators |
| 04/01/2009 | EP2041123A2 Fused cyclic compounds |
| 04/01/2009 | EP2041119A1 Pyrazolylbenzimidazole derivatives, compositions containing them and use thereof |
| 04/01/2009 | EP2041118A1 Substituted heterocyclic compounds and methods of use |
| 04/01/2009 | EP2041117A1 Heterocyclic substituted piperazine compounds with cxcr3 antagonist activity |
| 04/01/2009 | EP2041116A1 Phenyl substituted heteroaryl-derivatives and use thereof as anti-tumor agents |
| 04/01/2009 | EP2041115A1 New pyridine analogues |
| 04/01/2009 | EP2041114A2 Inhibitors of advanced glycation end products |
| 04/01/2009 | EP2041112A1 New pyridine analogues |
| 04/01/2009 | EP2041111A1 New pyridine analogues |
| 04/01/2009 | EP2041110A1 2 -oxyheteroarylamide derivatives as parp inhibitors |
| 04/01/2009 | EP2041107A1 3,4-di-substituted cyclobutene-1,2-diones as cxc-chemokine receptor ligands |
| 04/01/2009 | EP2041104A1 Cinnamoyl-piperazine derivatives and their use as par- i antagonists |
| 04/01/2009 | EP2041103A2 Derivatives of urea and related diamines, methods for their manufacture, and uses therefor |
| 04/01/2009 | EP2041102A2 Human protein tyrosine phosphatase inhibitors and methods of use |
| 04/01/2009 | EP2041101A1 Crystalline form of (trans-4- [ ( { 5- [ (3, 4 -di fluorophenyl) amino]-1,3, 4-oxadiazol-2-yl}carbonyl) amino]ph enyl } cyclohexyl) acetic acid |
| 04/01/2009 | EP2041100A1 Substituted 5- phenylamino- 1, 3, 4-oxadiaz0l-2-ylcarbonylamino-4-phenoxy-cyclohexane carboxylic acid as inhibitors of acetyl coenzyme a diacylglycerol acyltransferase |
| 04/01/2009 | EP2041099A1 1, 3, 4 -oxadiazole derivatives as dgat1 inhibitors |
| 04/01/2009 | EP2041096A1 2-amino benzimidazole derivatives and their use as modulators of small- conductance calcium-activated potatium channels |
| 04/01/2009 | EP2041095A1 Novel tyrosinase inhibitors, their process of preparation and their use in human medicine and in cosmetics |
| 04/01/2009 | EP2041094A1 Biarylcarboxyarylamides as vanilloid-1 receptor modulators |
| 04/01/2009 | EP2041093A1 Piperazinyl derivatives useful in the treatment of gpr38 receptor mediated diseases |
| 04/01/2009 | EP2041088A1 Glycine transporter-1 inhibitors |
| 04/01/2009 | EP2041087A1 2 -oxybenzamide derivatives as parp inhibitors |
| 04/01/2009 | EP2041086A1 Indole compounds |
| 04/01/2009 | EP2041085A1 Pyrrole derivatives and their methods of use |
| 04/01/2009 | EP2041084A1 Co-crystals of pyrrolidinones |
| 04/01/2009 | EP2041083A1 Zofenopril calcium |
| 04/01/2009 | EP2041082A1 Pyrrolidine derivatives having activity at the glyt1 transporter |
| 04/01/2009 | EP2041079A1 Arylsulfonyl naphthalene derivatives and uses thereof |
| 04/01/2009 | EP2041073A1 Cxcr2 inhibitors |
| 04/01/2009 | EP2041071A2 Biaryl compositions and methods for modulating a kinase cascade |
| 04/01/2009 | EP2041069A1 Benzyl amines, a process for their production and their use as anti-inflammatory agents |
| 04/01/2009 | EP2041068A1 Positively charged water-soluble prodrugs of ibuprofen with very fast skin penetration rate |
| 04/01/2009 | EP2041067A2 Cxer4 antagonists including diazine and triazine structures for the treatment of medical disorders |
| 04/01/2009 | EP2040794A2 Pharmaceutical formulations for iontophoretic tetracycline antibiotic delivery |
| 04/01/2009 | EP2040756A1 Composition containing metal-acidic amino acid chelate accelerating absorption of metal |
| 04/01/2009 | EP2040755A1 Combination of a cholinesterase inhibitor and a compound with 5-ht6 receptor affinity |
| 04/01/2009 | EP2040750A2 Methods and compositions for increasing the efficiency of therapeutic antibodies using gamma delta t cell activators |
| 04/01/2009 | EP2040741A1 Hyaluronic acid and hyaluronidase in the enhancement of lens regeneration |
| 04/01/2009 | EP2040738A1 Interleukin 21 and tyrosine kinase inhibitor combination therapy |
| 04/01/2009 | EP2040736A1 New formulation for increasing bioavailability of neurturin |
| 04/01/2009 | EP2040733A2 Method for elevating prolactin in mammals |
| 04/01/2009 | EP2040728A2 Fkbp-l and uses thereof |
| 04/01/2009 | EP2040725A2 Targeted delivery of drugs, therapeutic nucleic acids and functional nucleic acids to mammalian cells via intact killed bacterial cells |
| 04/01/2009 | EP2040724A2 Biotherapeutic compositions comprising probiotic escherichia coli and uses thereof |
| 04/01/2009 | EP2040722A1 Use of selected lactic acid bacteria for reducing infantile colic |
| 04/01/2009 | EP2040717A2 Method of enhancing the control of viruses on skin |
| 04/01/2009 | EP2040716A1 Cellulose sulfate for the treatment of rhinovirus infection |
| 04/01/2009 | EP2040715A1 Antimicrobial composition |
| 04/01/2009 | EP2040714A2 Method for the eradication of pathogens comprising generating molecular iodine in situ |
| 04/01/2009 | EP2040713A2 Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated deseases or conditions |
| 04/01/2009 | EP2040711A2 2-oxo-1,2-dihydroquinoline derivatives, compositions, and uses thereof as antiproliferative agents |
| 04/01/2009 | EP2040709A2 Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof |
| 04/01/2009 | EP2040708A2 Quercetin-containing compositions |
| 04/01/2009 | EP2040707A2 Combination of hmg-coa reductase inhibitors with phosphodiesterase 4 inhibitors for the treatment of inflammatory pulmonary diseases |
| 04/01/2009 | EP2040706A2 Modulators of muscarinic receptors |
| 04/01/2009 | EP2040705A2 Use of 2-benzoyl-imidazopyridines in therapeutics |
| 04/01/2009 | EP2040704A2 Pharmaceutical compositions comprising implitapide and methods of using same |
| 04/01/2009 | EP2040703A2 Derivatives of 2-benzoyl-imidazopyridines, preparation method thereof and use of same in therapeutics |
| 04/01/2009 | EP2040702A1 Use of ampk-activating imidazole derivatives, preparation process therefor and pharmaceutical compositions comprising them |
| 04/01/2009 | EP2040701A2 Aminoindazole urea derivatives |
| 04/01/2009 | EP2040700A1 N- (phenylmethyl) -2- (1h-pyraz0l-4-yl) acetamide derivatives as p2x7 antagonists for the treatment of pain, inflammation and neurodegeneration |
| 04/01/2009 | EP2040699A2 Methods and compositions for diagnostic and therapeutic targeting of cox-2 |
| 04/01/2009 | EP2040698A2 Oxime compounds and the use thereof |
| 04/01/2009 | EP2040697A2 Polymorphic form of duloxetine hydrochloride |
| 04/01/2009 | EP2040696A2 Compositions and use thereof for the treatment, co-treatment or prevention of inflammatory disorders |
| 04/01/2009 | EP2040695A2 Methods for the formulation and manufacture of artesunic acid for injection |
| 04/01/2009 | EP2040694A2 Use of ppar-alpha agonists to treat skeletal muscle wasting disorders |
| 04/01/2009 | EP2040693A2 Transdermal delivery of oleocanthal for relief of inflammation |
| 04/01/2009 | EP2040692A2 Medical use of n-phenylpropenoyl-amino acid derivatives and related compounds |
| 04/01/2009 | EP2040691A1 Aqueous pharmaceutical formulation of 4-[((4-carboxybutyl)-{2-[(4-phenethyl-benzyl)oxy]-phenethyl}amino)methyl]benzoic acid |
| 04/01/2009 | EP2040690A1 Inhibitors of cxcr2 |
| 04/01/2009 | EP2040689A2 Solution and method to reduce, treat and/or prevent oxidative stress and cell activation |